The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer

Xinyan Wu(Shandong University of Technology), Akhilesh Pandey(Mayo Clinic), Edward Gabrielson(Johns Hopkins University), Mustafa A. Barbhuiya(Johns Hopkins Medicine), Pavani Malla(Moffitt Cancer Center), Dhanashree Kelkar(Institute of Bioinformatics), Pamela Leal Rojas(Johns Hopkins University), Santosh Renuse(AstraZeneca (United States)), Saraswati Sukumar(Johns Hopkins University), Nupam P. Mahajan(Washington University in St. Louis), Vered Stearns(Johns Hopkins University), Muhammad Saddiq Zahari(Johns Hopkins University)
Oncotarget
November 25, 2016
Cited by 60


Related Papers